Analysts Maintain Optimistic Rating for Regeneron Pharmaceuticals with a Target Price of $850

Summary

John Newman maintains a positive outlook on Regeneron despite challenges with EYLEA, focusing on the potential of its semaglutide and trevogrumab combination for Alzheimer’s. Positive outcomes from Novo’s trials could boost investor interest, leading to further applications of trevogrumab and garetosmab. Newman reinforces a Buy rating with a target price of $850, while Bernstein also maintains a Buy rating with a $781 target.Tip Ranks

Impact Analysis

So basically, Newman is betting on Regeneron’s future potential in Alzheimer’s treatment, which is a bold move given the current challenges with EYLEA. The interesting part isn’t just the target price of $850, but the focus on semaglutide and trevogrumab, which could open new revenue streams if successful. The market seems to be missing the potential ripple effect of positive trial outcomes from Novo, which could significantly boost investor interest and drive applications of trevogrumab and garetosmab further. Despite mixed analyst ratings and a consensus price target of $739.95, the optimism around these new drug combinations could be a game-changer. The technical analysis suggests a long-term upward trend, but short-term signals are mixed, indicating potential volatility. Watching how Novo’s trials unfold could be key to understanding Regeneron’s trajectory.